Want to see RPID full AI Analyst Report?
Top Page
Rapid Micro Biosystems
(NASDAQ:RPID)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▲(0.50% Upside)
Action:Reiterated
Date:08/07/26
RPID scores below average primarily due to weak financial performance—deep ongoing losses, sustained cash burn, and rising leverage—despite improving revenue and gross margin trajectory. The earnings call added moderate support via reaffirmed revenue guidance and a clearer margin-improvement path, but execution and financing risks remain prominent. Technical indicators are mildly constructive, while valuation is constrained by unprofitability and lack of dividend support.
Positive Factors
Recurring consumables growth
Strong consumables momentum and 14% recurring revenue growth reflect a high-frequency, sticky revenue stream tied to each instrument. As the installed base and validations scale, consumables generate predictable, repeatable cash flows and margin leverage that support long‑term revenue visibility.
Negative Factors
Persistent operating losses
Large and ongoing operating losses show the business has not yet achieved operating leverage despite revenue gains. Continued negative profitability consumes capital, constrains reinvestment, and lengthens the period before the company can self‑fund growth or withstand adverse market conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables growth
Strong consumables momentum and 14% recurring revenue growth reflect a high-frequency, sticky revenue stream tied to each instrument. As the installed base and validations scale, consumables generate predictable, repeatable cash flows and margin leverage that support long‑term revenue visibility.
Read all positive factors
Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$84.20M
Dividend YieldN/A
Average Volume (3M)253.56K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth16.13%
EPS Growth-11.56%
CountryUS
Employees171
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,322,280
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.67Price Target Upside235.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$39.33M
Rapid Micro Biosystems Business Overview & Revenue Model
Company Description
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North Ameri...
How the Company Makes Money
Rapid Micro Biosystems makes money primarily by selling its Growth Direct systems and generating recurring revenue from the installed base through related consumables, service, and support. Key revenue streams typically include: (1) Instrument/pla...
Rapid Micro Biosystems Earnings Call Summary
Earnings Call Date:Aug 07, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.Positive Updates
Revenue Growth and Reaffirmed Full-Year Guidance
Total Q2 revenue of $8.1M, up 11% year-over-year (from $7.3M). Company reaffirmed full-year 2026 revenue guidance of $37M to $41M and guidance for 30 to 38 system placements.
Negative Updates
Continued Net Losses and Adjusted EBITDA Loss
Q2 net loss of $12.9M (vs. $11.9M prior year) and net loss per share of $0.27 (unchanged). Adjusted EBITDA loss was $10.3M in Q2 (worse than $10.1M in Q2 last year), indicating continued significant operating losses despite margin improvements.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Reaffirmed Full-Year Guidance
Total Q2 revenue of $8.1M, up 11% year-over-year (from $7.3M). Company reaffirmed full-year 2026 revenue guidance of $37M to $41M and guidance for 30 to 38 system placements.
Read all positive updates
Company Guidance
Rapid Micro reaffirmed full‑year 2026 guidance of $37–$41 million in revenue and 30–38 system placements, raised validation guidance to at least 27 completions (with ≥10 in Q3), and expects full‑year gross margin of ~20% (product margin mid‑to‑high single digits; service margin 45–50%). For Q3 they forecast at least $9.5 million of revenue (including ≥7 system placements) and Q3 gross margin ≥20%, with Q4 gross margin targeted in the mid‑to‑high‑20% range (product margin high‑single to low‑double digits; service margin ~50%). They also guided FY OpEx of $51–$53 million, $8 million of non‑cash expense (~$3M D&A, $5M stock comp), $1M CapEx, $1M interest income and $2M interest expense, reported ~ $20M cash at quarter‑end, expect to access a $10M debt tranche later this year (another $10M possible mid‑2027), and are targeting >20% average annual revenue growth and a 50%+ gross margin exit by 2028 with positive cash flow by end‑2028.Rapid Micro Biosystems Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
44
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.18M | 33.59M | 28.05M | 22.52M | 17.13M | 23.23M |
| Gross Profit | 3.53M | 7.61M | -109.00K | -5.49M | -8.54M | -7.74M |
| EBITDA | -46.31M | -42.74M | -43.51M | -49.33M | -58.55M | -69.25M |
| Net Income | -51.20M | -47.12M | -46.89M | -52.47M | -60.81M | -73.52M |
Balance Sheet | ||||||
| Total Assets | 58.45M | 74.85M | 98.17M | 143.45M | 190.65M | 241.17M |
| Cash, Cash Equivalents and Short-Term Investments | 19.77M | 38.30M | 50.73M | 92.05M | 108.65M | 193.50M |
| Total Debt | 23.48M | 23.87M | 6.17M | 7.35M | 7.97M | 400.00K |
| Total Liabilities | 40.70M | 41.65M | 22.82M | 25.46M | 26.48M | 20.19M |
| Stockholders Equity | 17.75M | 33.21M | 75.35M | 117.99M | 164.17M | 220.98M |
Cash Flow | ||||||
| Free Cash Flow | -40.39M | -31.91M | -45.52M | -46.93M | -65.29M | -58.18M |
| Operating Cash Flow | -40.06M | -31.06M | -44.15M | -45.08M | -58.55M | -54.96M |
| Investing Cash Flow | 7.12M | 14.33M | 36.66M | 42.15M | -93.47M | -13.29M |
| Financing Cash Flow | 29.29M | 19.77M | 203.00K | 149.00K | 693.00K | 216.75M |
Rapid Micro Biosystems Technical Analysis
Negative
1.99
Price Trends
1.89
Negative
2.07
Negative
2.89
Negative
Market Momentum
-0.06
Positive
33.50
Neutral
18.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Negative. The current price of 1.99 is above the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.89, and below the 200-day MA of 2.89, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.50 is Neutral, neither overbought nor oversold. The STOCH value of 18.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPID.
Rapid Micro Biosystems Risk Analysis
Rapid Micro Biosystems disclosed 69 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapid Micro Biosystems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $456.13M | -14.90 | -50.64% | ― | 9.27% | 41.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $98.35M | -1.88 | -96.66% | ― | -3.43% | 19.16% | |
51 Neutral | $76.14M | 6.51 | 9999.00% | ― | 3.26% | ― | |
49 Neutral | $84.20M | -1.53 | -177.04% | ― | 16.13% | -11.56% | |
49 Neutral | $95.51M | -2.33 | -100.30% | ― | 53.16% | 27.17% | |
46 Neutral | $199.90M | -2.07 | -1.91% | ― | 24.89% | 55.16% |
* Healthcare Sector Average
RPID
Rapid Micro Biosystems
1.68
-0.94
-35.88%
LUNG
Pulmonx
2.42
0.86
55.13%
LNSR
LENSAR
8.20
-4.45
-35.18%
HYPR
Hyperfine
0.89
-0.50
-35.83%
SGHT
Sight Sciences
8.14
3.94
93.81%
LUCD
Lucid Diagnostics
0.97
-0.05
-5.20%
Rapid Micro Biosystems Corporate Events
Executive/Board ChangesShareholder Meetings
Rapid Micro Biosystems Stockholders Approve Director and Auditor
Positive
May 28, 2026
Rapid Micro Biosystems held its annual meeting of stockholders on May 21, 2026, with a quorum present as 37,099,555 of 41,267,511 eligible Class A shares were represented in person or by proxy. At the meeting, stockholders elected Richard Kollende...
Private Placements and Financing
Rapid Micro Biosystems Announces Underwritten Equity and Warrant Offering
Neutral
May 19, 2026
On May 18, 2026, Rapid Micro Biosystems entered into an underwriting agreement with TD Securities (USA) LLC and Lake Street Capital Markets LLC for an underwritten offering of 3,581,000 shares of Class A common stock and associated Series A and Se...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.